Share Name Share Symbol Market Type Share ISIN Share Description
Summit Corporation LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +2.50p +1.25% 202.50p 271,032 16:20:53
Bid Price Offer Price High Price Low Price Open Price
200.00p 205.00p 202.50p 200.00p 200.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 25.4 -10.9 -10.6 - 142.28

Summit Corp (SUMM) Latest News

More Summit Corp News
Summit Corp Takeover Rumours

Summit Corp (SUMM) Share Charts

1 Year Summit Corp Chart

1 Year Summit Corp Chart

1 Month Summit Corp Chart

1 Month Summit Corp Chart

Intraday Summit Corp Chart

Intraday Summit Corp Chart

Summit Corp (SUMM) Discussions and Chat

Summit Corp Forums and Chat

Date Time Title Posts
21/5/201823:20Summit - Climbing to new heights23,574
12/11/201702:48Summit Therapeutics' View on Utrophin Modulation-
10/3/201615:43Professor Mark Wilcox Interview on C Diff1
23/5/201410:49Summit Corporation749
22/5/201417:46Summit Corporation plc37

Add a New Thread

Summit Corp (SUMM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-05-21 16:20:10204.0025,00051,000.00O
2018-05-21 15:33:26202.0025,00050,500.00O
2018-05-21 15:32:43202.0025,00050,500.00O
2018-05-21 15:30:49199.7050,00099,850.00O
2018-05-21 15:25:00204.001,0002,040.00O
View all Summit Corp trades in real-time

Summit Corp (SUMM) Top Chat Posts

Summit Corp Daily Update: Summit Corporation is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SUMM. The last closing price for Summit Corp was 200p.
Summit Corporation has a 4 week average price of 193.75p and a 12 week average price of 170p.
The 1 year high share price is 265p while the 1 year low share price is currently 140p.
There are currently 70,260,991 shares in issue and the average daily traded volume is 57,587 shares. The market capitalisation of Summit Corporation is £142,278,506.78.
luminoso: Thanks Hugus. It does not say much for the powers of research of the punters you describe from the nasdaq boards. Basically, those traders are pure momentum traders. If the share price is high, it must be good. If the share price is low, it must be bad ... or something does not add up. It also explains the share price of Sarepta at the moment. Of course many of these punters will be caught with their pants down, if Sarepta's share price implodes on fundamentals and Summit's share price explodes on likely approval of EZT. At some point, I expect Sarepta to make a move on EZT, either parts or the whole, as it will become increasingly clear to them that EZT is the most likely candidate around, currently, to make a difference to DMD boys. They have the cash still to achieve that but while the market sleeps with regard to EZT, they still have time before they have to make a move - around 48 week results time maybe ? The big question for me is - will they have any competition to acquire EZT the closer we get to results and, dare I say it, Approval ?
luminoso: Strengthening dollar has offset recent fall on nasdaq and prevented it being translated to AIM in the form of a few pence off our price. The inertia of the SUMM price works both ways and will only really react to quite dramatic moves in SMMT over on nasdaq, I guess.
artrade: Yes positive as all the calls tend to be and focus is on the 48 week data. Having been here a while I am not so excited that these milestone dates are so transformational and getting to market with the least ongoing dilution and board curve balls is what I would like to see. However will be needing more cash to progress the next study for ezutromid and even accelerated approval trial would be 18 months and start "early" 2019. I had hoped as a disease in real need, that if data was positive then accelerated regulatory approval and marketing would start in 2019 and not 2020/2021. Maybe I am not interpreting it right and others can clarify but do they see Summit start selling the drug alongside doing more trials(if good data on the 48 week phase out trial) in 2019 or 2020/21. Put to one side the languishing share price there are many boys who need effective treatment now ( I know a couple who I have seen deteriorate in the last 6mths to wheelchairs). Also the ongoing studies and trials on C difficle seem never ending and slow to progress.
gclark: That's a pretty good result for the placing, at a small discount to the share price. It gives the company the money for the developments.
football: Suppose I'm like most here clicked on the newsfeed and you see another big placing and think FFS not again! But then you look at the price of the placing and it's only 4-5p below the bid price which isn't that bad at all. As Hyper Al says it looks like someone wanted in pretty quick and maybe before any drug results hit the market, this placing would have taken a few days so the price probably was about £1.80 when agreed so they probably paid the full price to get in quick rather than spreading it over a couple weeks and maybe forcing the price up higher and costing them more or any positive test results which would of made the share price a lot higher. gla Summit Therapeutics launches placing to raise £15mln to advance its treatment for Duchenne Muscular Dystrophy 07:40 27 Mar 2018 The company said it expects to use the placing’s net proceeds to accelerate preparatory activities for a placebo-controlled clinical trial for DMD treatment ezutromid Read more
luminoso: Seems the Summit connection is boosting SRPT's share price !
algernon2: Singh said: “We recently spent time with Summit (SMMT) management meeting potential investors and reviewing the recent positive 24-week results from ezutromid in PhaseOUT DMD and the upcoming Phase 3 pivotal clinical trial initiations for ridinilazole in Clostridium difficile infection (CDI). Uniformly the meetings started with a certain degree of skepticism regarding drug development in Duchenne muscular dystrophy (DMD), and ended with engaged interest in the ezutromid development program and the potential for ridinilazole in CDI. Perhaps what stuck out most to us was that investors cautiously agreed with our thesis that the DMD development space is worthy of investment and that ridinilazole in CDI is a free option at the current SMMT share price. We reiterate our bullish stance on SMMT.” hTTps://
hugus maximus: filmster .... well done, I should have sold some but was waiting for a NASDAQ share price hike that didn't materialise. Share price drop has deepened over past few days as the dollar / pound rate moved against us .... uk shares are dollar led ... aside from overall 4% drop in Biotech this week as a result of general share drift. There is nothing to suggest any negative news about the progress of either DMD P2 or C Diff at Summit.
stephen2010: ALBA currently trading at 0.39p target price 6p making a nice 15 bagger. Please read the following: MARKET CAP PUZZLE ❖ Alba (market cap £8.4m) is in a resources neighbourhood populated with listed companies with much enhanced market capitalisations, such as UKOG.L (£134m) and JAY.L (£172m). With either shared project interests or adjacent tenements to these companies, Alba should trade at a much higher valuation than its current token value. Like Bluejay, Alba owns 100% of its ilmenite project. Direct comparisons with UKOG are also instructive. While both companies own other projects, UKOG’s 49.9% of Horse Hill Developments Limited (HHDL), when compared to Alba’s 18.1% means that Alba has approximately one third of the value of Horse Hill compared to UKOG but only about 7% of the market capitalisation. Once the market recognises these disparities, the room for growth in Alba’s share price is undeniable. VALUATION RATIONALE - Our valuation in this First Equity Limited initiation note uses a risked valuation approach for Alba’s two main projects, at Horse Hill and TBS. The Horse Hill licences are valued using independent published technical data from Schlumberger, Xodus and Nutech on the oil potential of the licences, along with our own assumptions on recovery rates, oil discovery value, resource and development risks factors. From this a risked value of $127m net to Alba on a ‘Base Case’ basis is derived for Horse Hill. Given the similar geology and economic potential of both TBS and Dundas, we have adopted a risked closeology valuation approach, by computing an NPV for Dundas of $223m and then applying a three-tiered risked probability calculation to arrive at a value of $54.7m for TBS. Once Alba announce its JORC resource and exploration target at TBS and Bluejay its Feasibility Study results, this number is likely to be revised upwards very rapidly, possibly up to $200m, representing up to 7p per share in additional shareholder value. We compute a valuation of $185m (£139m) for Alba, equating to 6.0p per share, of which 4.1p is attributed to the stake in Horse Hill, 1.8p for TBS. Given this analysis and wealth of valuation catalysts anticipated across the project portfolio in the coming months, we recommend the shares as a ‘BUY, with a Target Price of 6.0p, representing a potential 15 times plus uplift from the current share price.
hugus maximus: I know many of us are very optimistic about the value of Summits DMD work but find it difficult to quantify quite what the market cap might one day be. So an interesting post about Sarpeta (see below) that is very encouraging when you refer it's detail to the outlook for Summit. It explains how they are now advancing on further Exon skipping work that may help a further 8% of boys (in addition to their current 13% ... making a maximum of 21% of the DMD population that Sarepta could potentially help ... as opposed to Summit's potential 100%) Then whilst comparing the above, there seems to be much speculation about Sarepta's potential for acquisition: "As time passes and risk is reduced, the price tag for potential acquirers continues to move upward ... I'd say any deal at this point would conservatively start a share price of no less than $80," (EDIT - THAT WOULD MEAN THE SARPETA DMD WORK THEN PRESENTS A COMPANY MARKET CAP OF APPROX $4.5 billion) "... with such a price target still achievable simply by continuing to execute on the commercial side while progressing the DMD pipeline through the clinic. Recent price targets set by Oppenheimer ($76), Credit Suisse ($81), Nomura ($84) and Needham ($75) suggest I'm not too far off." Clearly this writer is a fan of Sarepta, but still an interesting measure of potential for work in the DMD field. I know Glyn acknowledged, whilst chatting at the last AGM, Summit will also be very ripe for the pickings if DMD P2 results start to show something positive. The article in full here:
Summit Corp share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180522 02:23:33